CA
ASBP

Crewe Advisors’s Aspire Biopharma ASBP Stock Holding History

Crewe Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.9K Hold
678
– – ﹤0.01% 508
2025
Q4 		$107K Hold
678
– – 0.01% 277
2025
Q3 		$168K Buy
678
+156
+30% +$78.1K 0.02% 231
2025
Q2 		$169K Buy
522
+261
+100% +$124K 0.02% 174
2025
Q1 		$183K Buy
+261
New +$1.8M 0.03% 145

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

Crewe Advisors's ASBP Position: Q1 2026 in Review

Crewe Advisors held its Aspire Biopharma (ASBP) position steady in Q1 2026 at 678 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #508.

Crewe Advisors first reported a position in ASBP in Q1 2025 and has held it in 5 quarters since. The position peaked at $183K in Q1 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Crewe Advisors held 678 shares of Aspire Biopharma worth $20.9K as of Q1 2026.
  • Crewe Advisors left its Aspire Biopharma share count unchanged in Q1 2026.
  • Aspire Biopharma made up ﹤0.01% of Crewe Advisors's portfolio in Q1 2026, its #508 holding.
  • Crewe Advisors first reported a position in Aspire Biopharma in Q1 2025 and has held it in 5 quarters since.
  • Crewe Advisors's Aspire Biopharma position peaked at $183K in Q1 2025.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.